Immunotherapy in glioblastoma: emerging options in precision medicine

Written by Tiffany R Hodges, Sherise D Ferguson & Amy B Heimberger

Immunotherapy for glioblastoma (GBM) provides a unique opportunity for targeted therapies for each patient, addressing individual variability in genes, tumor biomarkers and clinical profile. As immunotherapy has the potential to specifically target tumor cells with minimal risk to normal tissue, several immunotherapeutic strategies are currently being evaluated in clinical trials in GBM. With the Precision Medicine Initiative being announced in the President’s State of the Union Address in 2016, GBM immunotherapy provides a useful platform for changing the landscape in treating patients with difficult disease. Click here to view the full article

To view this content, please register now for access

It's completely free